Carlo Incerti Sells 16,500 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Carlo Incerti sold 16,500 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $28.73, for a total value of $474,045.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Dyne Therapeutics Stock Up 1.0 %

Shares of NASDAQ DYN opened at $29.99 on Thursday. The business’s 50 day moving average price is $32.31 and its two-hundred day moving average price is $35.25. The company has a market cap of $3.05 billion, a PE ratio of -8.42 and a beta of 1.10. Dyne Therapeutics, Inc. has a twelve month low of $10.03 and a twelve month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.39 EPS for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

Several large investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC raised its holdings in Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after acquiring an additional 669 shares during the period. Quantbot Technologies LP bought a new position in shares of Dyne Therapeutics during the third quarter worth approximately $34,000. Point72 DIFC Ltd bought a new stake in Dyne Therapeutics in the 3rd quarter valued at $36,000. US Bancorp DE grew its holdings in Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after buying an additional 1,212 shares in the last quarter. Finally, Values First Advisors Inc. bought a new position in Dyne Therapeutics during the 3rd quarter worth $62,000. 96.68% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on DYN shares. Morgan Stanley upped their price target on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Stifel Nicolaus increased their target price on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Chardan Capital reiterated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Finally, JPMorgan Chase & Co. lowered Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $43.00 to $35.00 in a report on Thursday, October 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.